{"id":"cacp29","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL2109636","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CaCP29 works by inhibiting the complement system, which plays a key role in inflammation and immune responses. By targeting the complement system, CaCP29 aims to reduce inflammation and prevent tissue damage.","oneSentence":"CaCP29 is a monoclonal antibody targeting the complement system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:59:03.534Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of Hidradenitis Suppurativa"}]},"trialDetails":[{"nctId":"NCT03971643","phase":"PHASE2","title":"Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum","status":"COMPLETED","sponsor":"InflaRx GmbH","startDate":"2019-05-16","conditions":"Pyoderma Gangrenosum","enrollment":19},{"nctId":"NCT03895801","phase":"PHASE2","title":"Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.","status":"COMPLETED","sponsor":"InflaRx GmbH","startDate":"2019-04-03","conditions":"Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)","enrollment":57},{"nctId":"NCT03712345","phase":"PHASE2","title":"Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA","status":"TERMINATED","sponsor":"InflaRx GmbH","startDate":"2018-10-15","conditions":"Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)","enrollment":20},{"nctId":"NCT03487276","phase":"PHASE2","title":"Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)","status":"COMPLETED","sponsor":"InflaRx GmbH","startDate":"2018-02-26","conditions":"Hidradenitis Suppurativa (HS)","enrollment":179},{"nctId":"NCT02246595","phase":"PHASE2","title":"Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction","status":"COMPLETED","sponsor":"InflaRx GmbH","startDate":"2014-04","conditions":"Severe Sepsis, Septic Shock","enrollment":72},{"nctId":"NCT01319903","phase":"PHASE1","title":"Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29","status":"COMPLETED","sponsor":"InflaRx GmbH","startDate":"2011-03","conditions":"Drug Safety","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IFX-1"],"phase":"phase_2","status":"active","brandName":"CaCP29","genericName":"CaCP29","companyName":"InflaRx GmbH","companyId":"inflarx-gmbh","modality":"Biologic","firstApprovalDate":"","aiSummary":"CaCP29 is a monoclonal antibody targeting the complement system. Used for Treatment of Hidradenitis Suppurativa.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}